poisar

Stocks · News reference

Palisade Bio shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $8 price target.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PALI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Palisade Bio to Participate in Upcoming Investor Conferences

    Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that management will participate in three major healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference (Sept 8-10), Morgan Stanley Global Healthcare Conference (Sept 14-16), and H.C. Wainwright Global Investment Conference (Sept 14-16). The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, into Phase 2 clinical trials for inflammatory bowel disease treatment.

    PALI
  2. Benzinga Newsdesk

    Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K

    Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The

    PALI